Cytomegalovirus

Current Opinion in Infectious Diseases

Volumn 27, Issue 6, 2014, Pages 554-559

  Griffiths, Paul ^a   Lumley, Sheila ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Congenital; Diagnosis; Preemptive therapy; Randomized controlled trial; Treatment

Indexed keywords

BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; DNA POLYMERASE; GANCICLOVIR; HYPERIMMUNE GLOBULIN; LETERMOVIR; PLACEBO; VALGANCICLOVIR; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CYTOSINE; PHOSPHONIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE; RIBONUCLEOSIDE;

BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CONGENITAL INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA PACKAGING; ENZYME PHOSPHORYLATION; HUMAN; NEPHROTOXICITY; NONHUMAN; PLACENTA; PREGNANCY; PREGNANT WOMAN; REVIEW; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGY;

ACETATES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DISEASE TRANSMISSION, INFECTIOUS; DOUBLE-BLIND METHOD; FEMALE; GANCICLOVIR; HUMANS; MALE; ORGAN TRANSPLANTATION; ORGANOPHOSPHONATES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBONUCLEOSIDES;

EID: 84927796943     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000107     Document Type: Review

References (44)

1. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21:597-605.
2. Cope AV, Sweny P, Sabin C, et al. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52:200-205.
3. Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484-1490.
4. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036.
5. Emery VC, Cope AV, Bowen EF, et al. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999; 190:177-182.
6. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324:1057-1059.
7. Marty FM, Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011; 1:555-562.
8. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111:5403-5410.
9. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227-1236.
10. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014; 370:1781-1789.
11. Hamirally S, Kamil JP, Ndassa-Colday YM, et al. Viral mimicry of Cdc2/cyclindependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 2009; 5:e1000275.
12. Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009; 19:215-229.
13. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011; 11:284-292.
14. Clinical Trials Gov: Identifier-NCT01611974. Maribavir for treatment of resistant or refractory CMV infections in transplant recipients. 2014. Ref type: online source.
15. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18:233-246.
16. Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006; 50:3470-3472.
17. Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol 2002; 12:115-127.
18. Newcomb WW, Juhas RM, Thomsen DR, et al. The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol 2001; 75:10923-10932.
19. Brown JC, Newcomb WW. Herpesvirus capsid assembly: insights from structural analysis. Curr Opin Virol 2011; 1:142-149.
20. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17:355-363.
21. Cannon MJ, Westbrook K, Levis D, et al. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med 2012; 54:351-357.
22. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175:1080-1086.
23. KimberlinDW,Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003; 143:16-25.
24. Stagno S, Reynolds DW, Tsiantos A, et al. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J Infect Dis 1975; 132:568-577.
25. Walter S, Atkinson C, Sharland M, et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonatal Ed 2008; 93:280-285.
26. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis 2008; 197:836-845.
27. KimberlinDW. Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. ID Week abstract 2014.
28. Williams EJ, Kadambari S, Berrington JE, et al. Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Arch Dis Child Fetal Neonatal Ed 2014; 99:F230-F236.
29. Barbi M, Binda S, Caroppo S. Diagnosis of congenital CMV infection via dried blood spots. Rev Med Virol 2006; 16:385-392.
30. Boppana SB, Ross SA, Novak Z, et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010; 303:1375-1382.
31. Atkinson C, Emery VC, Griffiths PD. Development of a novel single tube nested PCR for enhanced detection of cytomegalovirus DNA from dried blood spots. J Virol Methods 2014; 196:40-44.
32. Boppana SB, Ross SA, Shimamura M, et al. Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. N Engl J Med 2011; 364:2111-2118.
33. Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 2010; 20:311-326.
34. Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States. Clin Infect Dis 2006; 43:1143-1151.
35. de Vries JJ, van Zwet EW, Dekker FW, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 2013; 23:241-249.
36. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17:253-276.
37. Revello MG, Fabbri E, Furione M, et al. Role of prenatal diagnosis and counseling in the management of 735 pregnancies complicated by primary human cytomegalovirus infection: a 20-year experience. J Clin Virol 2011; 50:303-307.
38. Guerra B, Simonazzi G, Banfi A, et al. Impact of diagnostic and confirmatory tests and prenatal counseling on the rate of pregnancy termination among women with positive cytomegalovirus immunoglobulin M antibody titers. Am J Obstet Gynecol 2007; 196:221-226.
39. Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005; 353:1350-1362.
40. Griffiths PD. Progress towards interrupting intrauterine transmission of cytomegalovirus? Rev Med Virol 2006; 16:1-4.
41. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 2014; 370:1316-1326.
42. Hamprecht K, Maschmann J, Vochem M, et al. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 2001; 357:513-518.
43. Yeager AS, Palumbo PE, Malachowski N, et al. Sequelae of maternally derived cytomegalovirus infections in premature infants. J Pediatr 1983; 102:918-922.
44. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). A randomized trial to prevent congenital cytomegalovirus (CMV). 8. 2013. ClinicalTrials.gov Identifier: NCT01376778. Online source.